Sugi Predict

Sugi Predict / Targets / KDM3A

KDM3A

Lysine-specific demethylase 3A · Q9Y4C1 · KDM3A on Sugi Atlas →

12,457 patent compounds predicted against KDM3A, 7,790 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL528024 SCHEMBL528024 0.61 8/20
Thiocyanic Acid Thiocyanic Acid (SCHEMBL736619) 0.52 8/20
Dipyridyl Dipyridyl (SCHEMBL213432) 0.70 6/20
SCHEMBL913277 SCHEMBL913277 1.00 5/20
SCHEMBL70700 SCHEMBL70700 0.78 5/20
SCHEMBL528023 SCHEMBL528023 0.75 5/20
SCHEMBL449879 SCHEMBL449879 0.68 5/20
SCHEMBL647098 SCHEMBL647098 0.65 5/20
SCHEMBL186166 SCHEMBL186166 0.63 5/20
Thiocyanic Acid Thiocyanic Acid (SCHEMBL736618) 0.62 5/20
Isothiocyanate Isothiocyanate (SCHEMBL992138) 0.62 5/20
SCHEMBL992139 SCHEMBL992139 0.62 5/20
SCHEMBL40395 SCHEMBL40395 0.61 5/20
SCHEMBL118817 SCHEMBL118817 0.61 5/20
SCHEMBL220538 SCHEMBL220538 0.61 5/20
SCHEMBL789419 SCHEMBL789419 0.55 5/20
SCHEMBL831972 SCHEMBL831972 0.53 5/20
SCHEMBL528803 SCHEMBL528803 0.53 5/20
SCHEMBL1170173 SCHEMBL1170173 0.50 5/20
SCHEMBL72377 SCHEMBL72377 1.00 4/20

Clinical trials — most relevant to KDM3A by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis PHASE1/PHASE2RECRUITING
IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome PHASE2ACTIVE_NOT_RECRUITING
IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome PHASE2ACTIVE_NOT_RECRUITING
Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) PHASE2ACTIVE_NOT_RECRUITING
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes PHASE1/PHASE2COMPLETED
Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations PHASE2SUSPENDED
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma PHASE1/PHASE2COMPLETED
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma PHASE1UNKNOWN
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors PHASE1COMPLETED
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load PHASE1COMPLETED
Safety and Pharmacokinetic Profile of CKD-581 PHASE1COMPLETED
Lysine-specific Demethylase 1 and Salt-sensitivity in Humans nanACTIVE_NOT_RECRUITING
The Danish TURNER Cryopreservation Study nanRECRUITING
Model to Predict pCR and IrAEs in Early Stage Non-small Cell Lung Cancer nanUNKNOWN
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
The Association of G9a Protein and Clinical Outcome of Patients With Vulvar Cancer nanUNKNOWN
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
The Molecular Pathogenesis Study of Cataract nanUNKNOWN
Impact of a Monoamine Oxidase Inhibitor on the Phenotype of Blood Mononucleated Cells in Patients With COVID-19 nanCOMPLETED
Prevalence and Clinical Effect of IDH1/2 Mutations in Patients With Acute Myeloid Leukemia nanUNKNOWN
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma nanUNKNOWN
Mechanisms of Immune Deficiency nanUNKNOWN
Screening of IDH1 and IDH2 Gene Mutations in Adult Acute Myeloid Leukemia for Possible Targeted Therapy nanUNKNOWN
Expression of TET1 Gene in Acute Leukaemia nanUNKNOWN
The Crosstalk Between the Epigenome and Mitochondria in SCI nanNOT_YET_RECRUITING
OBServatory of Compassionate Use of IVOsidenib in France for Patients With Acute Myeloid Leukemia nanRECRUITING
EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors nanUNKNOWN
Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer (NSCLC) As Part of Adjuvant Therapy and Preventive Strategy nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a KDM3A binder may also engage these)

ProteinNameSimilarity
Q6PCM1 — 1.000 Q6PCM1 →
Q5HZN1 — 1.000 Q5HZN1 →
Q63679 — 0.999 Q63679 →
Q5ZIX8 — 0.994 Q5ZIX8 →
Q8C0C0 — 0.992 Q8C0C0 →
Q14865 — 0.992 Q14865 →
Q80Y19 — 0.991 Q80Y19 →
Q9Z2U2 — 0.991 Q9Z2U2 →
Q92613 — 0.991 Q92613 →
Q7ZXV6 — 0.991 Q7ZXV6 →
Q09YG9 — 0.991 Q09YG9 →
Q8N4X5 — 0.990 Q8N4X5 →
NFRKB Nuclear factor related to kappa-B-binding protein 0.990 landscape →
Q9NQW6 — 0.990 Q9NQW6 →
Q5TKR9 — 0.990 Q5TKR9 →
Q8BHZ4 — 0.990 Q8BHZ4 →
A6QP06 — 0.990 A6QP06 →
Q9H4I2 — 0.990 Q9H4I2 →
Q13129 — 0.989 Q13129 →
F6YVB9 — 0.989 F6YVB9 →
Q6DFV7 — 0.989 Q6DFV7 →
Q6A037 — 0.989 Q6A037 →
Q8BM75 — 0.989 Q8BM75 →
Q9FY74 — 0.989 Q9FY74 →
P62292 — 0.989 P62292 →
Q2IBE6 — 0.989 Q2IBE6 →
Q96T21 — 0.989 Q96T21 →
PHF20 PHD finger protein 20 0.989 landscape →
Q5R789 — 0.989 Q5R789 →
Q8BZ32 — 0.989 Q8BZ32 →